urbantravels
disjecta membra
- Messages
- 1,333
- Location
- Los Angeles, CA
http://www.newscientist.com/article/dn21065-chronic-fatigue-syndrome-eased-by-cancer-drug.html
http://www.tv2.no/nyheter/innenriks...reakthrough-can-solve-cfsmystery-3615631.html
Full paper is here:
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026358
http://www.tv2.no/nyheter/innenriks...reakthrough-can-solve-cfsmystery-3615631.html
Full paper is here:
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026358
In conclusion, we have shown that B-lymphocyte depletion with the monoclonal anti-CD20 antibody Rituximab, two infusions two weeks apart, is associated with significant, though generally transient clinical responses, with CFS symptom improvement in two thirds of the included patients. No major toxicity was observed in 12 months follow-up. Even though this study is small, it is a randomised, double-blind, and placebo-controlled study showing significant differences in favour of the Rituximab group, and with general improvement of all CFS symptoms. Thus, we believe that B-cell depletion targets a central player in the pathogenesis of the CFS disease, directly or indirectly. Whether this mechanism applies to specific subsets of CFS patients or the group as a whole is a subject for further research. While this study can be interpreted as preliminary, being the first to describe the treatment principle in CFS except for our pilot case series [4], we believe the results are best compatible with an autoimmune disease mechanism and that the presented findings may have a major impact on the direction of biomedical research in CFS. Based on new pilot patient experiences, we have now started two new open-label phase-II studies investigating Rituximab treatment with two infusions two weeks apart (as in the present study) followed by maintenance Rituximab infusions at 3, 6, 10 and 15 months, to further explore this treatment principle in CFS (ClinicalTrials.gov, NCT01156909 and NCT01156922). The present study may be interpreted as a proof of principle. The next studies will indicate to what extent the patients actually over time may recover through B-cell depletion treatment.